Drug Trial Radar · NCT06548815
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4
Last checked: Nov 19, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Aug 29, 2022
Primary completion
Mar 24, 2023
Study completion Mar 24, 2023
Sponsor
- Lead sponsor
- Gan and Lee Pharmaceuticals, USAIndustry
- Sponsor type
- Industry
- First posted
- Aug 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This trial is conducted in China. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single-dose GZR4.
Conditions
- Diabetes
Interventions
GZR4Drug
Ascending single doses - 4 dose levels.
PlaceboDrug
Ascending single doses - 4 dose levels.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TEAETime frame: Baseline to Day29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gan & Lee Pharmaceuticals Co., Ltd
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.